Latest News in the pharma Industry

UPDATED: COVID-19 Pharma Development Tracker

23 Nov 2020

The latest coronavirus updates and developments impacting the global pharmaceutical supply chain

Indian authority extends comments deadline for API anti-dumping probe

19 Nov 2020

Early trial results hail Moderna's COVID-19 vaccine as 94.5% effective

17 Nov 2020

Data also show that mRNA-1273 remains stable at 2–8°, the temperature of a standard home or medical refrigerator, for 30 days.

Seqirus to build $800m influenza vaccine manufacturing facility in Australia

17 Nov 2020

The facility will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere.

European Commission wraps up CureVac COVID-19 vaccine supply deal

17 Nov 2020

Europeans set to benefit from the EC's authorization of COVID-19 candidate vaccine supply agreement, securing up to 405 million doses of CVnCoV

Recipharm and Medspray establish joint venture to exploit novel softmist technology

17 Nov 2020

Resyca BV will provide a "unique offering" to the market — environmentally friendly, softmist spray nozzle technology for pharmaceutical applications.

Vibalogics establishes US presence with virotherapy facility in Boston

16 Nov 2020

The specialist CDMO's $150 million 3-year investment plan will provide a complete suite of virotherapy services to support drug developers and their most "revolutionary" products.

Stelis starts next phase of investment into its biologics manufacturing facility

11 Nov 2020

This phase sees the CDMO start work on installing two 2,000-L single-use bioreactor trains in its mammalian cGMP facility.

Pfizer and BioNTech COVID vaccine proves 90% effective

10 Nov 2020

Results from a Phase III clinical study found Pfizer and BioNTech's mRNA-based vaccine candidate, BNT162b2, is more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection, the companies announced Monday...

Recipharm invests in its pMDI valves production capacity

10 Nov 2020

The expansion will bolster the CDMO's offering by ensuring it can fulfil the forecasted increase in demand for respiratory devices.

Altimmune signs up Lonza to manufacture intranasal COVID-19 vaccine

10 Nov 2020

Altimmune adds Lonza as a manufacturing partner for supply of AdCOVID, its single-dose intranasal vaccine candidate for COVID-19.

CDMOs benefit from COVID-19 impact, says CPhI Annual Report

10 Nov 2020

CMO growth, however, hampered by innovator approvals from mega-cap pharma.